Activity Description:

This series is a dedicated educational activity designed to keep healthcare professionals up-to-date with the latest clinical practice guidelines relevant to blood cancer treatment. As clinical practice guidelines are created and/or updated for the Colorado Blood Cancer Institute, individual meetings will be organized to provide a comprehensive review of each guideline. These sessions will focus on specific treatment protocols for various blood cancers, ensuring that clinicians understand the evidence behind each recommendation and how to apply it in clinical practice. Detailed supporting data, including recent research findings and clinical trial results, will be presented to enhance understanding and promote evidence-based decision-making. The goal of these meetings is to empower healthcare providers with the knowledge and tools necessary to deliver the highest standard of care to blood cancer patients, ensuring that they stay informed about advancements in treatment options and best practices.

Target Audience: 

CBCI providers (physicians and APPs) and nurses who care for CBCI patients.

Learning Objectives:

• Identify practice changes for the management and treatment of patients with blood cancer. 
• Analyze new practice guidelines and incorporate updates to treatment practices.
• Utilize multi-disciplinary approaches in the diagnosis, management, and treatment of patients.

Moderator:

Alison Collings, NP-C

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies.*

*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

Accreditation:

The HCA Healthcare Continental Division is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

Credit Designation:

The HCA Healthcare Continental Division designates this live activity for a maximum of 1.0 AMA PRA Category 1^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support:  

This Activity was developed without support from any ineligible company.*The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical services is owned, or controlled by, and ACCME defined ineligible company.

Disclosure: 

The HCA Healthcare Continental Division is committed to providing CME that is balanced, objective, and evidenced-based. In accordance with the Accreditation Council for Continuing Medical Education Standards for Integrity and Independence all parties involved in content development are required to disclose all conflicts of interest with ACCME defined ineligible companies. The HCA Healthcare Continental Division has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity. The CME planning committee who are in a position to control the content of this CME Activity, have no relevant financial relationships with ineligible companies to disclose.